Akcea Therapeutics (United States)

Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, is a biopharmaceutical company focused on developing and commercializing RNA-targeted therapies for lipid disorders. Based in Cambridge, Massachusetts, Akcea developed Tegsedi (inotersen) for hereditary transthyretin-mediated amyloidosis and treatments for familial chylomicronemia syndrome (FCS). The company specializes in antisense oligonucleotide technology for rare genetic diseases affecting lipid metabolism.